Adaptive Biotechnologies Corporation (ADPT) Guidance & Earnings Results
On 2026-07-29 Adaptive Biotechnologies Corporation raised guidance: "MRD revenue guidance raised to $268M-$278M from $260M-$270M; total OpEx guidance narrowed to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADPTAdaptive Biotechnologies CorporationFollow ADPT — free
—
Price chart with a free account
- Market cap
- 4.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Raised | MRD revenue guidance raised to $268M-$278M from $260M-$270M; total OpEx guidance narrowed to $350M-$355M · full year |
| 5 May 26 | Raised | MRD revenue guidance raised to $260M-$270M from $255M-$265M · full year |
| 5 Feb 26 | Raised | MRD revenue guidance $255M-$265M for FY2026 · full year |
| 5 Nov 25 | Raised | MRD revenue guidance raised to $202-207M from $190-200M; operating spend guidance reduced to $335-340M from $335-345M; cash burn guidance reduced to $45-50M from $45-55M · full year |
| 5 Aug 25 | Raised | FY2025 MRD revenue raised to $190-200M from $180-190M; FY2025 total company cash burn lowered to $45-55M from $50-60M; FY2025 total company operating expenses $335-345M · full year |
Adaptive Biotechnologies Corporation — questions
- What guidance did Adaptive Biotechnologies Corporation give?
- On 2026-07-29: "MRD revenue guidance raised to $268M-$278M from $260M-$270M; total OpEx guidance narrowed to $350M-$355M"
- When does Adaptive Biotechnologies Corporation report earnings?
- Adaptive Biotechnologies Corporation's next earnings report is expected on 2026-11-04.
Every figure on this page comes from Adaptive Biotechnologies Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.